Developer docs
API playgroundTry for free, no card

Search company profiles

Prolium

Full company profile

uuid02c27wp

Namestring
Prolium
Legal namestring
Prolium Bioscience
Websiteurl
proliumbio.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Prolium Bioscience is a privately held, clinical-stage biotechnology company headquartered in New York City that develops therapies for severe autoimmune diseases. The company's stated focus is on patients with treatment-refractory systemic sclerosis, systemic lupus erythematosus, and lupus nephritis—an underserved population with limited therapeutic options. Prolium operates as a single-asset biotech built around a bispecific antibody platform.

The company's sole pipeline candidate is PRO-203, a CD20xCD3 bispecific T-cell engager designed to deplete pathogenic B-cells by simultaneously engaging CD20 on B-cells and CD3 on T-cells for targeted cytolysis. PRO-203 was in-licensed from KeyMed Biosciences and InnoCare Pharma, giving Prolium global rights in all non-oncology indications and ex-Asia rights in oncology. Prior Phase 1/2 data in relapsed/refractory non-Hodgkin lymphoma showed a 59% complete response rate and 82% overall response rate at therapeutic doses, which the company cites as supporting a potential best-in-class profile in autoimmune applications. As of mid-2026, Prolium had dosed healthy volunteers in a single ascending dose study, treated five lupus nephritis patients in an investigator-initiated study, and dosed the first patient in a multinational Phase 1/2 study in systemic sclerosis.

Prolium is pre-revenue and has no commercial products. Its revenue model is pharmaceutical product sales upon regulatory approval, distributed through specialty pharmacies, hospital systems, and direct physician administration. The company raised a $50 million Series A in March 2026 led by founding investor RTW Investments to fund clinical development and R&D expansion. Leadership consists of founder and CEO Scott Requadt, CMO Salim Mujais, VP of Clinical Development Niki Bili, and VP of CMC & Manufacturing Bob Huang, supported by a small (1-10 employee) team.

Short descriptiontext

Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager, for severe autoimmune diseases including systemic sclerosis and lupus nephritis. The New York-based company in-licensed the asset from KeyMed and InnoCare.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody therapy, autoimmune disease therapeutics, T-cell engager platform, clinical stage biotechnology, B-cell depletion therapy
Industry1 code
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Autoimmune Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotechnology company developing PRO-203 for severe autoimmune diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Prolium Bioscience is developing PRO-203, a bispecific CD20xCD3 T-cell engager antibody in-licensed from KeyMed Biosciences and InnoCare Pharma, for the treatment of severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. The company is currently running a single ascending dose study in healthy volunteers and plans a multinational Phase 1/2 study in systemic sclerosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 59% complete response rate and 82% overall response rate in relapsed/refractory Non-Hodgkin Lymphoma at therapeutic doses
Product overview1 text field

Prolium Bioscience is a clinical-stage biotechnology company with a single core product pipeline. PRO-203 is a bispecific CD20xCD3 T-cell engager in-licensed from KeyMed Biosciences and InnoCare Pharma, representing the company's primary therapeutic candidate for treating severe autoimmune diseases.

Product and service2 records
1PRO-203
CategoryBiologic therapeutic candidate / bispecific antibody
Description

PRO-203 is a bispecific CD20xCD3 T-cell engager antibody being developed by Prolium Bioscience for severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The therapeutic candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. It is intended for patients with treatment-refractory severe autoimmune disorders.

2PRO-203 Phase 1/2 Clinical Study in Systemic Sclerosis
CategoryClinical trial program
Description

A multinational Phase 1/2 clinical trial evaluating PRO-203 in patients with systemic sclerosis. The study is being conducted by Prolium Bioscience to assess safety, tolerability, and efficacy of the bispecific CD20xCD3 T-cell engager in this severe autoimmune indication. The trial is part of Prolium's core clinical development program.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-03
Description

Prolium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from KeyMed Biosciences. KeyMed previously showed 59% CR and 82% ORR in NHL Phase 1/2 trials.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-03
Description

Prolium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from InnoCare Pharma, in addition to KeyMed Biosciences.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AbbVie is the commercial partner for epcoritamab (CD20xCD3 bispecific) and has a broad immunology franchise including HUMIRA, SKYRIZI, and RINVOQ. As a leader in autoimmune disease therapeutics, it represents a major incumbent competitor and potential strategic acquirer for Prolium's technology.

TypeDirect peer
Description

Cabaletta Bio is a clinical-stage biotechnology company developing CD19 CAR-T cell therapies for autoimmune diseases, including lupus and systemic sclerosis. It is directly comparable to Prolium in pursuing deep B-cell depletion for severe autoimmune indications.

TypeBroad incumbent
Description

Roche developed glofitamab and mosunetuzumab, both CD20xCD3 bispecific antibodies approved or in late-stage development for lymphoma. As an established leader in the CD20xCD3 space, Roche is a direct competitive incumbent for Prolium's mechanism, though with vastly broader portfolio scale.

TypeDirect peer
Description

Genmab is a biotechnology company specializing in antibody therapeutics, including the CD20xCD3 bispecific T-cell engager epcoritamab. It is directly comparable to Prolium given its leadership in CD20xCD3 bispecific antibody technology and its application across oncology and emerging autoimmune indications.

TypeEmerging player
Description

Argenx is a biotechnology company developing antibody-based therapies for severe autoimmune diseases, with lead asset efgartigimod (FcRn antagonist) approved for myasthenia gravis. It is comparable to Prolium in focusing on biologics for severe autoimmune indications, though with a different mechanism.

TypeEmerging player
Description

Caribou Biosciences is developing allogeneic CAR-T cell therapies for autoimmune diseases and oncology. It is comparable to Prolium in pursuing B-cell-directed therapies for severe autoimmune indications, though using an allogeneic cell therapy platform.

TypeOthers
Description

KeyMed Biosciences is the originator and licensor of PRO-203 to Prolium. It is comparable as the developer of the underlying CD20xCD3 bispecific antibody technology and remains a strategic partner and potential ecosystem participant for Prolium.

TypeDirect peer
Description

Regeneron is developing odronextamab, a CD20xCD3 bispecific antibody, and has deep antibody engineering capabilities (VelociSuite). It is comparable to Prolium in pursuing CD20xCD3 bispecifics, though at significantly larger scale and with broader pipeline scope.

TypeEmerging player
Description

Cullinan Therapeutics develops T-cell engagers and other oncology and autoimmune therapies, including immune-mediated disease programs. It is comparable to Prolium as an emerging clinical-stage company with TCE-focused pipeline strategy.

TypeDirect peer
Description

Kyverna Therapeutics is developing CD19 CAR-T cell therapies for autoimmune diseases including lupus nephritis and other B-cell-driven conditions. It is directly comparable to Prolium in targeting severe autoimmune diseases via B-cell depletion, though using a cell therapy rather than a bispecific antibody.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prolium

Biopharmaceuticals / Autoimmune Disease Therapeuticsproliumbio.com

Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager, for severe autoimmune diseases including systemic sclerosis and lupus nephritis. The New York-based company in-licensed the asset from KeyMed and InnoCare.

What Prolium does

Prolium Bioscience is a privately held, clinical-stage biotechnology company headquartered in New York City that develops therapies for severe autoimmune diseases. The company's stated focus is on patients with treatment-refractory systemic sclerosis, systemic lupus erythematosus, and lupus nephritis—an underserved population with limited therapeutic options. Prolium operates as a single-asset biotech built around a bispecific antibody platform.

The company's sole pipeline candidate is PRO-203, a CD20xCD3 bispecific T-cell engager designed to deplete pathogenic B-cells by simultaneously engaging CD20 on B-cells and CD3 on T-cells for targeted cytolysis. PRO-203 was in-licensed from KeyMed Biosciences and InnoCare Pharma, giving Prolium global rights in all non-oncology indications and ex-Asia rights in oncology. Prior Phase 1/2 data in relapsed/refractory non-Hodgkin lymphoma showed a 59% complete response rate and 82% overall response rate at therapeutic doses, which the company cites as supporting a potential best-in-class profile in autoimmune applications. As of mid-2026, Prolium had dosed healthy volunteers in a single ascending dose study, treated five lupus nephritis patients in an investigator-initiated study, and dosed the first patient in a multinational Phase 1/2 study in systemic sclerosis.

Prolium is pre-revenue and has no commercial products. Its revenue model is pharmaceutical product sales upon regulatory approval, distributed through specialty pharmacies, hospital systems, and direct physician administration. The company raised a $50 million Series A in March 2026 led by founding investor RTW Investments to fund clinical development and R&D expansion. Leadership consists of founder and CEO Scott Requadt, CMO Salim Mujais, VP of Clinical Development Niki Bili, and VP of CMC & Manufacturing Bob Huang, supported by a small (1-10 employee) team.

Prolium firmographics

Firmographics
Name
Prolium
Legal name
Prolium Bioscience
Website
https://proliumbio.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a bispecific CD20xCD3 T-cell engager, for severe autoimmune diseases including systemic sclerosis and lupus nephritis. The New York-based company in-licensed the asset from KeyMed and InnoCare.
Ownership category
akta.pro rank

Prolium industry classification

Industry
Product category
Biopharmaceuticals / Autoimmune Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Bispecific antibody therapy
  • Autoimmune disease therapeutics
  • T-cell engager platform
  • Clinical stage biotechnology
  • B-cell depletion therapy

Where Prolium is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prolium business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical stage biotechnology company developing PRO-203 for severe autoimmune diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Prolium product offering

Product offering

Core offering

Prolium Bioscience is developing PRO-203, a bispecific CD20xCD3 T-cell engager antibody in-licensed from KeyMed Biosciences and InnoCare Pharma, for the treatment of severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. The company is currently running a single ascending dose study in healthy volunteers and plans a multinational Phase 1/2 study in systemic sclerosis.

Product overview

Prolium Bioscience is a clinical-stage biotechnology company with a single core product pipeline. PRO-203 is a bispecific CD20xCD3 T-cell engager in-licensed from KeyMed Biosciences and InnoCare Pharma, representing the company's primary therapeutic candidate for treating severe autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • PRO-203 PRO-203 is a bispecific CD20xCD3 T-cell engager antibody being developed by Prolium Bioscience for severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The therapeutic candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. It is intended for patients with treatment-refractory severe autoimmune disorders.
  • PRO-203 Phase 1/2 Clinical Study in Systemic Sclerosis A multinational Phase 1/2 clinical trial evaluating PRO-203 in patients with systemic sclerosis. The study is being conducted by Prolium Bioscience to assess safety, tolerability, and efficacy of the bispecific CD20xCD3 T-cell engager in this severe autoimmune indication. The trial is part of Prolium's core clinical development program.

Quantifiable outcome

  • 59% complete response rate and 82% overall response rate in relapsed/refractory Non-Hodgkin Lymphoma at therapeutic doses

Companies that use Prolium

Customer profile

Segments1 record

Ideal customer profiles1 record

Prolium technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Prolium partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • KeyMed BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 3 March 2026Prolium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from KeyMed Biosciences. KeyMed previously showed 59% CR and 82% ORR in NHL Phase 1/2 trials.
  • InnoCare PharmacoreOEM/ Whitelabel/ Licensing Partner · 3 March 2026Prolium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from InnoCare Pharma, in addition to KeyMed Biosciences.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Prolium competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: AbbVie is the commercial partner for epcoritamab (CD20xCD3 bispecific) and has a broad immunology franchise including HUMIRA, SKYRIZI, and RINVOQ. As a leader in autoimmune disease therapeutics, it represents a major incumbent competitor and potential strategic acquirer for Prolium's technology.
  • Roche: Roche developed glofitamab and mosunetuzumab, both CD20xCD3 bispecific antibodies approved or in late-stage development for lymphoma. As an established leader in the CD20xCD3 space, Roche is a direct competitive incumbent for Prolium's mechanism, though with vastly broader portfolio scale.

Direct peers

  • Cabaletta Bio: Cabaletta Bio is a clinical-stage biotechnology company developing CD19 CAR-T cell therapies for autoimmune diseases, including lupus and systemic sclerosis. It is directly comparable to Prolium in pursuing deep B-cell depletion for severe autoimmune indications.
  • Genmab: Genmab is a biotechnology company specializing in antibody therapeutics, including the CD20xCD3 bispecific T-cell engager epcoritamab. It is directly comparable to Prolium given its leadership in CD20xCD3 bispecific antibody technology and its application across oncology and emerging autoimmune indications.
  • Regeneron Pharmaceuticals: Regeneron is developing odronextamab, a CD20xCD3 bispecific antibody, and has deep antibody engineering capabilities (VelociSuite). It is comparable to Prolium in pursuing CD20xCD3 bispecifics, though at significantly larger scale and with broader pipeline scope.
  • Kyverna Therapeutics: Kyverna Therapeutics is developing CD19 CAR-T cell therapies for autoimmune diseases including lupus nephritis and other B-cell-driven conditions. It is directly comparable to Prolium in targeting severe autoimmune diseases via B-cell depletion, though using a cell therapy rather than a bispecific antibody.

Emerging players

  • Argenx: Argenx is a biotechnology company developing antibody-based therapies for severe autoimmune diseases, with lead asset efgartigimod (FcRn antagonist) approved for myasthenia gravis. It is comparable to Prolium in focusing on biologics for severe autoimmune indications, though with a different mechanism.
  • Caribou Biosciences: Caribou Biosciences is developing allogeneic CAR-T cell therapies for autoimmune diseases and oncology. It is comparable to Prolium in pursuing B-cell-directed therapies for severe autoimmune indications, though using an allogeneic cell therapy platform.
  • Cullinan Therapeutics: Cullinan Therapeutics develops T-cell engagers and other oncology and autoimmune therapies, including immune-mediated disease programs. It is comparable to Prolium as an emerging clinical-stage company with TCE-focused pipeline strategy.

Others

  • KeyMed Biosciences: KeyMed Biosciences is the originator and licensor of PRO-203 to Prolium. It is comparable as the developer of the underlying CD20xCD3 bispecific antibody technology and remains a strategic partner and potential ecosystem participant for Prolium.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Prolium social profiles

Digital presence

Prolium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prolium leadership team

Management profile

Number of profiles

Profiles4 records

Prolium funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prolium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolium

What does Prolium do?

Prolium Bioscience is developing PRO-203, a bispecific CD20xCD3 T-cell engager antibody in-licensed from KeyMed Biosciences and InnoCare Pharma, for the treatment of severe autoimmune diseases including systemic sclerosis, systemic lupus erythematosus, and lupus nephritis. The candidate works by engaging CD3 on T-cells to deplete CD20-expressing pathogenic B-cells. The company is currently running a single ascending dose study in healthy volunteers and plans a multinational Phase 1/2 study in systemic sclerosis.

Is Prolium a public or private company?

Prolium is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prolium founded?

Prolium was founded in 2026. It employs 1 to 10 people.

Where is Prolium based?

Prolium is headquartered in New York, United States, in the North America region.

How does Prolium make money?

One revenue line is on record: drug Development and Commercialization.

Who are Prolium's main competitors?

Broad incumbents on record are AbbVie and Roche. Direct peers are Cabaletta Bio, Genmab, Regeneron Pharmaceuticals and Kyverna Therapeutics. Emerging players are Argenx, Caribou Biosciences and Cullinan Therapeutics. KeyMed Biosciences is listed as an others.

Does Prolium have an API?

No public API is recorded for Prolium.

What industry is Prolium in?

Prolium's product category is Biopharmaceuticals / Autoimmune Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Phirda诺诚健华:左手肿瘤,右手自免Nocera Health is advancing its autoimmune pipeline with Soficitinib and Fadeucravacitinib reaching key endpoints, and Obinutuzumab's ITP filing accepted. The company's differentiated strategy targets unmet needs, with multiple first-in-class products. Its dual-tumor and autoimmune focus aims to create a second growth curve.Phirda谁是中国血液肿瘤老大In 2025, BTK inhibitor Zelnitib and BCMA CAR-T Carvykti from Chinese firms Baidi and Legend sold nearly $6 billion, with Q1 sales reaching $1.7 billion. The article details a competitive landscape with Baidi and Legend leading, followed by Novartis, Yasheng, and DiZhi, and Biotech firms using bispecifics to compete.pharmaphorumKidney biotech R1's $78m debut, and other biofinancingsMarch has seen a cluster of biotech financing rounds, with six companies raising between $40 million and $78 million for candidates spanning chronic kidney disease, cancer cell therapies, and autoimmune diseases. R1 Therapeutics emerged from stealth with a $77.5 million Series A for a pan-phosphate transporter inhibitor (AP306) licensed from China's Alebund Pharmaceuticals, Crossbow Therapeutics raised $77 million for T-cell engagers targeting myeloid cancers, and Excalipoint Therapeutics secured $68.7 million for a trispecific cancer antibody. Additional rounds included Prolium Bioscience's $50 million Series A for an autoimmune TCE, Unnatural Products' $45 million Series B for macrocyclic peptide development, Vima Therapeutics' expansion to $100 million Series A for a movement disorder candidate, and Mestag Therapeutics' $40 million for a bispecific antibody heading to Phase 1 trials.FinSMEsProlium Bioscience Raises $50M in Series A FundingProlium Bioscience, a NYC-based clinical stage biotechnology company, raised $50 million in Series A funding led by RTW Investments. The company will use the proceeds to expand operations and R&D efforts for PRO-203, a bispecific CD20xCD3 antibody being developed for systemic sclerosis and other severe autoimmune diseases. Prolium in-licensed global rights in all non-oncology indications and ex-Asia rights for oncology indications to PRO-203 from KeyMed Biosciences and InnoCare Pharma.The Pharma LetterProlium launches with $50 million Series A financingProlium Bioscience announced a $50 million Series A financing to develop PRO-203, a CD20xCD3 T-cell engager for severe autoimmune disease. The financing was led by founding investor RTW Investments.GlobeNewswireProlium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune DiseaseProlium Bioscience launched with a $50 million Series A financing led by founding investor RTW Investments to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune diseases including systemic sclerosis and lupus nephritis. The company has begun dosing healthy volunteers in an ongoing single ascending dose study and expects to initiate a multinational Phase 1/2 study in systemic sclerosis in Q2 2026, with five treatment-refractory lupus nephritis patients already treated in an investigator-initiated study. Prolium in-licensed global rights in all non-oncology indications and ex-Asia oncology rights to PRO-203 from KeyMed Biosciences and InnoCare Pharma, with prior Phase 1/2 data in relapsed/refractory Non-Hodgkin Lymphoma showing a 59% complete response rate and 82% overall response rate at therapeutic doses.Venture Capital Access OnlineProlium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune DiseaseProlium Bioscience launched with a $50 million Series A financing led by founding investor RTW Investments to develop PRO-203, a bispecific CD20xCD3 T-cell engager for severe autoimmune diseases including systemic sclerosis and lupus. The company has begun dosing healthy volunteers in a single ascending dose study and has treated five patients with treatment-refractory systemic lupus erythematosus and lupus nephritis in an investigator-initiated study. Prolium plans to initiate a multinational Phase 1/2 study in systemic sclerosis in Q2 2026 and expects substantial data readouts across several autoimmune disorders within two years.TechStartupsTop Startup and Tech Funding News – March 3, 2025Multiple technology startups announced funding rounds on March 3, 2026, collectively raising approximately $890.5 million across sectors including AI infrastructure, healthcare, biotech, GovTech, cybersecurity, and home services. Ayar Labs led the day with a $500 million Series E co-led by NVIDIA and AMD, valuing the photonic interconnect company at $3.8 billion, while Grow Therapy secured $150 million Series D and CHAMP Titles raised $55 million for digital DMV modernization. The funding activity spanned companies including Prolium Bioscience ($50M for autoimmune T-cell therapy), Fig Security ($38M for enterprise security data lineage), DeepIP ($25M for AI patent workflows), Pronto ($25M for Indian home services), RenoFi ($22M for home renovation loans), and RAS Luxury Skincare ($7.5M for premium D2C beauty).PR NewswireKeymed Biosciences Announces Annual Results of 2024Keymed Biosciences announced its 2024 annual results, reporting total revenue of RMB 430 million (21% year-on-year increase) and R&D expenditures of approximately RMB 730 million (23% YoY increase), with cash reserves of RMB 2.1 billion. The company secured three new drug approvals from China's NMPA for its flagship drug Stapokibart (CM310) across atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis, generating approximately RMB 40 million in sales within three and a half weeks of launch. Keymed expanded its global partnerships through licensing agreements with Belenos Biosciences, Platina Medicines Ltd, and Timberlyne Therapeutics, receiving combined upfront payments exceeding $61 million plus equity stakes, while also entering a joint development agreement with Prolium for CM355.